Endometrial Stromal Tumors: The New WHO Classification

被引:127
作者
Conklin, Christopher M. J. [1 ]
Longacre, Teri A. [2 ]
机构
[1] Surrey Mem Hosp, Dept Pathol, Surrey, BC V3V 1Z2, Canada
[2] Stanford Univ, Dept Pathol, Stanford, CA 94305 USA
关键词
low-grade endometrial stromal sarcoma; high-grade endometrial stromal sarcoma; undifferentiated uterine sarcoma; immunohistochemistry; molecular genetics; SMOOTH-MUSCLE TUMORS; JAZF1-JJAZ1 GENE FUSION; CORD-LIKE DIFFERENTIATION; IN-SITU HYBRIDIZATION; NUCLEAR BETA-CATENIN; HIGH-GRADE SARCOMAS; CLEAR-CELL SARCOMA; MESENCHYMAL TUMORS; IMMUNOHISTOCHEMICAL ANALYSIS; UTERINE SARCOMAS;
D O I
10.1097/PAP.0000000000000046
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Endometrial stromal tumors are rare uterine mesenchymal neoplasms that have intrigued pathologists for years, not only because they commonly pose diagnostic dilemmas, but also because the classification and pathogenesis of these tumors has been widely debated. The current World Health Organization recognizes 4 categories of endometrial stromal tumor: endometrial stromal nodule (ESN), low-grade endometrial stromal sarcoma (LG-ESS), high-grade endometrial stromal sarcoma (HG-ESS), and undifferentiated uterine sarcoma (UUS). uterine sarcoma. These categories are defined by the presence of distinct translocations as well as tumor morphology and prognosis. Specifically, the JAZF1-SUZ12 (formerly JAZF1-JJAZ1) fusion identifies a large proportion of ESN and LG-ESSs, whereas the YWHAE-FAM22 translocation identifies HG-ESSs. The latter tumors appear to have a prognosis intermediate between LG-ESS and UUS, which exhibits no specific translocation pattern. This review (1) presents the clinicopathologic features of endometrial stromal tumors; (2) discusses their immunophenotype; and (3) highlights the recent advances in molecular genetics which explain their pathogenesis and lend support for a new classification system.
引用
收藏
页码:383 / 393
页数:11
相关论文
共 98 条
[1]   Undifferentiated carcinoma of the endometrium [J].
Altrabulsi, B ;
Malpica, A ;
Deavers, MT ;
Bodurka, DC ;
Broaddus, R ;
Silva, EG .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2005, 29 (10) :1316-1321
[2]   Transition of endometrial stromal sarcoma into high-grade sarcoma [J].
Amant, Frederic ;
Woestenborghs, Heidi ;
Vandenbroucke, Vanessa ;
Berteloot, Patrick ;
Neven, Patrick ;
Moerman, Philippe ;
Vergote, Ignace .
GYNECOLOGIC ONCOLOGY, 2006, 103 (03) :1137-1140
[3]   Endometrial stromal sarcoma metastatic to the lung - A detailed analysis of 16 patients [J].
Aubry, MC ;
Myers, JL ;
Colby, TV ;
Leslie, KO ;
Tazelaar, HD .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2002, 26 (04) :440-449
[4]   Inhibin and CD99 (MIC2) expression in uterine stromal neoplasms with sex-cord-like elements [J].
Baker, RJ ;
Hildebrandt, RH ;
Rouse, RV ;
Hendrickson, MR ;
Longacre, TA .
HUMAN PATHOLOGY, 1999, 30 (06) :671-679
[5]   Expression of progesterone receptor A and B isoforms in low-grade endometrial stromal sarcoma [J].
Balleine, RL ;
Earls, PJ ;
Webster, LR ;
Mote, PA ;
deFazio, A ;
Harnett, PR ;
Clarke, CL .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 2004, 23 (02) :138-144
[6]   UTERINE STROMAL SARCOMA FOLLOWING TAMOXIFEN TREATMENT [J].
BEER, TW ;
BUCHANAN, R ;
BUCKLEY, CH .
JOURNAL OF CLINICAL PATHOLOGY, 1995, 48 (06) :596-596
[7]   Distinction of endometrial stromal sarcomas from 'hemangiopericytomatous' tumors using a panel of immunohistochemical stains [J].
Bhargava, R ;
Shia, J ;
Hummer, AJ ;
Thaler, HT ;
Tornos, C ;
Soslow, RA .
MODERN PATHOLOGY, 2005, 18 (01) :40-47
[8]  
Blom R, 1999, INT J GYNECOL CANCER, V9, P98
[9]   Imatinib mesylate (Gleevec)-targeted kinases are expressed in uterine sarcomas [J].
Caudell, JJ ;
Deavers, MT ;
Slomovitz, BM ;
Lu, KH ;
Broaddus, RR ;
Gershenson, DM ;
Ramondetta, LM .
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2005, 13 (02) :167-170
[10]   PRIMARY UTERINE ENDOMETRIAL STROMAL NEOPLASMS - A CLINICOPATHOLOGICAL STUDY OF 117 CASES [J].
CHANG, KL ;
CRABTREE, GS ;
LIMTAN, SK ;
KEMPSON, RL ;
HENDRICKSON, MR .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1990, 14 (05) :415-438